NTQ 1062
Alternative Names: NTQ-1062Latest Information Update: 09 Aug 2024
At a glance
- Originator Nanjing Chia Tai Tianqing Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer; Solid tumours
Most Recent Events
- 27 May 2024 Nanjing Chia-tai Tianqing Pharmaceutical completes a phase I trial in Solid tumours (Late-stage disease) in China (PO) (NCT06172309)
- 28 Dec 2023 Phase-I clinical trials in Breast cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in China (PO) (NCT06172322)
- 15 Dec 2023 Nanjing Chia-tai Tianqing Pharmaceutical plans a phase I trial for Breast cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable) in China (PO, Tablet) (NCT06172322)